Renal anemia: from relative insufficiency of EPO to imbalance of erythropoiesis and eryptosis.
EPO
Eryptosis
Erythropoiesis
Renal anemia
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
23
05
2024
accepted:
03
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
aheadofprint
Résumé
Chronic kidney disease has emerged as a major health issue both in China and worldwide. Renal anemia frequently occurs in patients with chronic kidney disease, and its severity and incidence rate increase as the disease progresses. Over the last 30 years, the administration of exogenous EPO and EPO stimulants has been employed to alleviate renal anemia, suggesting that a relative deficiency in EPO may be a primary cause. However, this approach has overshadowed other contributing factors, particularly eryptosis, which results from the reduced lifespan of red blood cells. Numerous studies reveal that there are nephrogenic and extrarenal EPO secretion indicating that an absolute deficiency of EPO is not always present in patients. Therefore, this paper speculates that renal anemia may arise when EPO-driven erythropoiesis fails to adequately compensate for aggravating eryptosis. Other factors including iron metabolism disorder, uremic toxin accumulation, inflammatory state, oxidative stress, and secondary hyperparathyroidism affect EPO reactivity bone marrow hematopoiesis and eryptosis, leading to an imbalance between red blood cell production and destruction, and cause anemia ultimately. More further studies on the pathogenesis and treatment of renal anemia would be expected to provide evidence to support our opinion.
Identifiants
pubmed: 38982020
doi: 10.1007/s11255-024-04146-x
pii: 10.1007/s11255-024-04146-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Shandong Provincial Natural Science Fund Committee
ID : ZR2021MH394
Organisme : Shandong Provincial Health and Wellness Committee
ID : M-2022265
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR (2017) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. J PLoS ONE 11(7):e0158765
doi: 10.1371/journal.pone.0158765
Li Y, Shi H, Wang WM, Peng A, Jiang GR, Zhang JY, Ni ZH, He LQ, Niu JY, Wang NS, Mei CL, Xu XD, Guo ZY, Yuan WJ, Yan HD, Deng YY, Yu C, Cen J, Zhang Y, Chen N (2016) Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine 95(24):e3872. https://doi.org/10.1097/md.0000000000003872
doi: 10.1097/md.0000000000003872
pubmed: 27310973
pmcid: 4998459
Stauffer ME, Fan T (2014) Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 9(1):e84943. https://doi.org/10.1371/journal.pone.0084943
doi: 10.1371/journal.pone.0084943
pubmed: 24392162
pmcid: 3879360
Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero JJ (2020) Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J 13(5):821–827. https://doi.org/10.1093/ckj/sfaa054
doi: 10.1093/ckj/sfaa054
pubmed: 33123358
pmcid: 7577763
van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R (2020) Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 21(1):88. https://doi.org/10.1186/s12882-020-01746-4
doi: 10.1186/s12882-020-01746-4
pubmed: 32143582
pmcid: 7060645
Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, Lopes AA, Asahi K, van Haalen H, James G, Dhalwani N, Pecoits-Filho R, Bieber B, Robinson BM, Pisoni RL (2020) Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3–5 nondialysis CKD. J Ren Nutr 30(5):404–414. https://doi.org/10.1053/j.jrn.2019.11.003
doi: 10.1053/j.jrn.2019.11.003
pubmed: 31980326
Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH (2009) Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology 14(2):240–246. https://doi.org/10.1111/j.1440-1797.2008.01065.x
doi: 10.1111/j.1440-1797.2008.01065.x
pubmed: 19207866
Yahata K, Seta K, Kikuchi Y, Koizumi M, Murata M, Wada H, Murakami S, Ohishi M, Tsuji H (2019) Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study. Clin Exp Nephrol 23(10):1211–1220. https://doi.org/10.1007/s10157-019-01767-w
doi: 10.1007/s10157-019-01767-w
pubmed: 31342291
Abdelazeem B, Shehata J, Abbas KS, El-Shahat NA, Malik B, Savarapu P, Eltobgy M, Kunadi A (2022) The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials. PLoS ONE 17(4):e0266243. https://doi.org/10.1371/journal.pone.0266243
doi: 10.1371/journal.pone.0266243
pubmed: 35363823
pmcid: 8974992
Locatelli F, Minutolo R, De Nicola L, Del Vecchio L (2022) Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors. Drugs 82(16):1565–1589. https://doi.org/10.1007/s40265-022-01783-3
doi: 10.1007/s40265-022-01783-3
pubmed: 36350500
pmcid: 9645314
Imeri F, Nolan KA, Bapst AM, Santambrogio S, Abreu-Rodríguez I, Spielmann P, Pfundstein S, Libertini S, Crowther L, Orlando IMC, Dahl SL, Keodara A, Kuo W, Kurtcuoglu V, Scholz CC, Qi W, Hummler E, Hoogewijs D, Wenger RH (2019) Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype. Kidney Int 95(2):375–387. https://doi.org/10.1016/j.kint.2018.08.043
doi: 10.1016/j.kint.2018.08.043
pubmed: 30502050
Artunc F, Risler T (2007) Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 22(10):2900–2908. https://doi.org/10.1093/ndt/gfm316
doi: 10.1093/ndt/gfm316
pubmed: 17556407
Dahl SL, Pfundstein S, Hunkeler R, Dong X, Knöpfel T, Spielmann P, Scholz CC, Nolan KA, Wenger RH (2022) Fate-mapping of erythropoietin-producing cells in mouse models of hypoxaemia and renal tissue remodelling reveals repeated recruitment and persistent functionality. Acta Physiol 234(3):e13768. https://doi.org/10.1111/apha.13768
doi: 10.1111/apha.13768
Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589(Pt 6):1251–1258. https://doi.org/10.1113/jphysiol.2010.195057
doi: 10.1113/jphysiol.2010.195057
pubmed: 21078592
Nangaku M, Eckardt K-U (2006) Pathogenesis of renal anemia. Semin Nephrol 26(4):261–268
doi: 10.1016/j.semnephrol.2006.06.001
pubmed: 16949463
Nolan KA, Wenger RH (2018) Source and microenvironmental regulation of erythropoietin in the kidney. Curr Opin Nephrol Hypertens 27(4):277–282. https://doi.org/10.1097/mnh.0000000000000420
doi: 10.1097/mnh.0000000000000420
pubmed: 29746306
Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815–826. https://doi.org/10.1053/j.ajkd.2016.12.011
doi: 10.1053/j.ajkd.2016.12.011
pubmed: 28242135
Shu S, Wang Y, Zheng M, Liu Z, Cai J, Tang C, Dong Z (2019) Hypoxia and hypoxia-inducible factors in kidney injury and repair. Cells 8(3):207. https://doi.org/10.3390/cells8030207
doi: 10.3390/cells8030207
pubmed: 30823476
pmcid: 6468851
Bonomini M, Del Vecchio L, Sirolli V, Locatelli F (2016) New treatment approaches for the anemia of CKD. Am J Kidney Dis 67(1):133–142. https://doi.org/10.1053/j.ajkd.2015.06.030
doi: 10.1053/j.ajkd.2015.06.030
pubmed: 26372086
Sato K, Kumagai N, Suzuki N (2019) Alteration of the DNA methylation signature of renal erythropoietin-producing cells governs the sensitivity to drugs targeting the hypoxia-response pathway in kidney disease progression. Front Genet 10:1134. https://doi.org/10.3389/fgene.2019.01134
doi: 10.3389/fgene.2019.01134
pubmed: 31798631
pmcid: 6863978
Suzuki N, Yamamoto M (2016) Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch 468(1):3–12. https://doi.org/10.1007/s00424-015-1740-2
doi: 10.1007/s00424-015-1740-2
pubmed: 26452589
Kaneko K, Sato Y, Uchino E, Toriu N, Shigeta M, Kiyonari H, Endo S, Fukuma S, Yanagita M (2022) Lineage tracing analysis defines erythropoietin-producing cells as a distinct subpopulation of resident fibroblasts with unique behaviors. Kidney Int 102(2):280–292. https://doi.org/10.1016/j.kint.2022.04.026
doi: 10.1016/j.kint.2022.04.026
pubmed: 35644281
Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, Abe M, Kiyomoto H, Ito S, Yamamoto M (2013) Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 24(10):1599–1616. https://doi.org/10.1681/asn.2013010030
doi: 10.1681/asn.2013010030
pubmed: 23833259
pmcid: 3785278
Sato K, Hirano I, Sekine H, Miyauchi K, Nakai T, Kato K, Ito S, Yamamoto M, Suzuki N (2019) An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts. Sci Rep 9(1):11254. https://doi.org/10.1038/s41598-019-47766-5
doi: 10.1038/s41598-019-47766-5
pubmed: 31375751
pmcid: 6677766
Dahl SL, Bapst AM, Khodo SN, Scholz CC, Wenger RH (2022) Fount, fate, features, and function of renal erythropoietin-producing cells. Pflugers Arch 474(8):783–797. https://doi.org/10.1007/s00424-022-02714-7
doi: 10.1007/s00424-022-02714-7
pubmed: 35750861
pmcid: 9338912
Xu Y, Kong X, Li J, Cui T, Wei Y, Xu J, Zhu Y, Zhu X (2021) Mild hypoxia enhances the expression of HIF and VEGF and triggers the response to injury in rat kidneys. Front Physiol 12:690496. https://doi.org/10.3389/fphys.2021.690496
doi: 10.3389/fphys.2021.690496
pubmed: 34248676
pmcid: 8267573
Koury ST, Bondurant MC, Semenza GL, Koury MJ (1993) The use of in situ hybridization to study erythropoietin gene expression in murine kidney and liver. Microsc Res Tech 25(1):29–39. https://doi.org/10.1002/jemt.1070250106
doi: 10.1002/jemt.1070250106
pubmed: 8353306
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21(12):2151–2156. https://doi.org/10.1681/asn.2010010116
doi: 10.1681/asn.2010010116
pubmed: 21115615
pmcid: 3014028
Li JH, Luo JF, Jiang Y, Ma YJ, Ji YQ, Zhu GL, Zhou C, Chu HW, Zhang HD (2019) Red blood cell lifespan shortening in patients with early-stage chronic kidney disease. Kidney Blood Press Res 44(5):1158–1165. https://doi.org/10.1159/000502525
doi: 10.1159/000502525
pubmed: 31550724
Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wüthrich RP (2004) Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66(3):1206–1211. https://doi.org/10.1111/j.1523-1755.2004.00880.x
doi: 10.1111/j.1523-1755.2004.00880.x
pubmed: 15327419
Tanaka M, Komaba H, Fukagawa M (2018) Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial 22(3):242–245. https://doi.org/10.1111/1744-9987.12685
doi: 10.1111/1744-9987.12685
pubmed: 29767854
Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Kajavadara C, Valani D, Jain MR (2022) Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Curr Res Pharmacol Drug Discov 3:100102. https://doi.org/10.1016/j.crphar.2022.100102
doi: 10.1016/j.crphar.2022.100102
pubmed: 35570856
pmcid: 9096675
Tanaka S, Kitamura H, Tsuruya K, Kitazono T, Nakano T (2022) Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study. Clin Exp Nephrol 26(9):867–879. https://doi.org/10.1007/s10157-022-02227-8
doi: 10.1007/s10157-022-02227-8
pubmed: 35507237
Hamza E, Vallejo-Mudarra M, Ouled-Haddou H, García-Caballero C, Guerrero-Hue M, Santier L, Rayego-Mateos S, Larabi IA, Alvarez JC, Garçon L, Massy ZA, Choukroun G, Moreno JA, Metzinger L, Meuth VM (2023) Indoxyl sulfate impairs erythropoiesis at BFU-E stage in chronic kidney disease. Cell Signal 104:110583. https://doi.org/10.1016/j.cellsig.2022.110583
doi: 10.1016/j.cellsig.2022.110583
pubmed: 36596353
Duangchan T, Rattanasompattikul M, Chitchongyingcharoen N, Mas-Oodi S, Promkan M, Rongkiettechakorn N, Korpraphong S, Supokawej A (2022) Indoxyl sulfate impairs in vitro erythropoiesis by triggering apoptosis and senescence. Exp Biol Med 247(15):1350–1363. https://doi.org/10.1177/15353702221097320
doi: 10.1177/15353702221097320
Hsieh CC, Chan MJ, Su YJ, Fu JF, Wang IK, Chen CY, Weng CH, Huang WH, Hsu CW, Yen TH (2021) Bone marrow hypocellularity in patients with end-stage kidney disease. Healthcare 9(11):1452. https://doi.org/10.3390/healthcare9111452
doi: 10.3390/healthcare9111452
pubmed: 34828498
pmcid: 8621268
Dias GF, Tozoni SS, Bohnen G, Grobe N, Rodrigues SD, Meireles T, Nakao LS, Pecoits-Filho R, Kotanko P, Moreno-Amaral AN (2021) Uremia and inadequate oxygen supply induce eryptosis and intracellular hypoxia in red blood cells. Cell Physiol Biochem 55(4):449–459. https://doi.org/10.33594/000000396
doi: 10.33594/000000396
pubmed: 34259420
Gutiérrez L, Caballero N, Fernández-Calleja L, Karkoulia E, Strouboulis J (2020) Regulation of GATA1 levels in erythropoiesis. IUBMB Life 72(1):89–105. https://doi.org/10.1002/iub.2192
doi: 10.1002/iub.2192
pubmed: 31769197
Wang Z, Wang P, Zhang J, Gong H, Zhang X, Song J, Nie L, Peng Y, Li Y, Peng H, Cui Y, Li H, Hu B, Mi J, Liang L, Liu H, Zhang J, Ye M, Yazdanbakhsh K, Mohandas N, An X, Han X, Liu J (2023) The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis. Nucleic Acids Res 51(10):4774–4790. https://doi.org/10.1093/nar/gkad167
doi: 10.1093/nar/gkad167
pubmed: 36929421
pmcid: 10250228
Sankaran VG, Weiss MJ (2015) Anemia: progress in molecular mechanisms and therapies. Nat Med 21(3):221–230. https://doi.org/10.1038/nm.3814
doi: 10.1038/nm.3814
pubmed: 25742458
pmcid: 4452951
Lukas L, Dietmar F, Katharina K, Günter W (2021) Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients 13(11):3732–3732
doi: 10.3390/nu13113732
Xuekun X, Wenbo Z, Huishan S (2016) Role of erythropoietin in renal anemia therapy. Tropic J Pharmaceut Res 15(5):1083–1088
doi: 10.4314/tjpr.v15i5.26
Gafter-Gvili A, Schechter A, Rozen-Zvi B (2019) Iron deficiency anemia in chronic kidney disease. Acta Haematol 142(1):44–50. https://doi.org/10.1159/000496492
doi: 10.1159/000496492
pubmed: 30970355
Bazeley JW, Wish JB (2022) Recent and emerging therapies for iron deficiency in anemia of CKD: a review. Am J Kidney Dis 79(6):868–876. https://doi.org/10.1053/j.ajkd.2021.09.017
doi: 10.1053/j.ajkd.2021.09.017
pubmed: 34758368
Gutiérrez OM (2021) Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep 6(9):2261–2269. https://doi.org/10.1016/j.ekir.2021.05.020
doi: 10.1016/j.ekir.2021.05.020
pubmed: 34514189
pmcid: 8418942
Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J (2019) Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 23(5):407–421. https://doi.org/10.1080/14728222.2019.1599358
doi: 10.1080/14728222.2019.1599358
pubmed: 30907175
Portolés J, Martín L, Broseta JJ, Cases A (2021) Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med 8:642296. https://doi.org/10.3389/fmed.2021.642296
doi: 10.3389/fmed.2021.642296
Li J, Haase VH, Hao CM (2023) Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia. Kidney Dis 9(1):1–11. https://doi.org/10.1159/000527835
doi: 10.1159/000527835
Wang X, Wei C, Zhao D, Sun X, Zhu F, Mei Y, Ma Q, Cai G, Chen X, Li P (2023) Iron supplements concomitant within hypoxia-inducible factor prolyl hydroxylase domain inhibitors in the treatment of chronic kidney disease anemia. Kidney Dis 9(6):485–497. https://doi.org/10.1159/000533304
doi: 10.1159/000533304
Hamza E, Metzinger L, Metzinger-Le Meuth V (2020) Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review. Cells 9(9):2039. https://doi.org/10.3390/cells9092039
doi: 10.3390/cells9092039
pubmed: 32899941
pmcid: 7565991
Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, Maeda H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T (2021) Indoxyl sulfate contributes to mTORC1-induced renal fibrosis via the OAT/NADPH oxidase/ROS pathway. Toxins 13(12):909. https://doi.org/10.3390/toxins13120909
doi: 10.3390/toxins13120909
pubmed: 34941746
pmcid: 8706756
Gluba-Brzózka A, Franczyk B, Olszewski R, Rysz J (2020) The influence of inflammation on anemia in CKD patients. Int J Mol Sci 21(3):725. https://doi.org/10.3390/ijms21030725
doi: 10.3390/ijms21030725
pubmed: 31979104
pmcid: 7036805
Wang CY, Babitt JL (2016) Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol 23(3):189–197. https://doi.org/10.1097/moh.0000000000000236
doi: 10.1097/moh.0000000000000236
pubmed: 26886082
pmcid: 4993159
Ganz T (2019) Anemia of inflammation. N Engl J Med 381(12):1148–1157. https://doi.org/10.1056/NEJMra1804281
doi: 10.1056/NEJMra1804281
pubmed: 31532961
Wang J, Erlacher M, Fernandez-Orth J (2022) The role of inflammation in hematopoiesis and bone marrow failure: what can we learn from mouse models? Front Immunol 13:951937. https://doi.org/10.3389/fimmu.2022.951937
doi: 10.3389/fimmu.2022.951937
pubmed: 36032161
pmcid: 9403273
Amnuay K, Srisawat N, Wudhikarn K, Assanasen T, Polprasert C (2019) Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients. Hematol Rep 11(3):8183. https://doi.org/10.4081/hr.2019.8183
doi: 10.4081/hr.2019.8183
pubmed: 31579107
pmcid: 6761458
Rao S, Zhang J, Lin J, Wan J, Chen Y (2022) Association of red blood cell life span with abnormal changes in cardiac structure and function in non-dialysis patients with chronic kidney disease stages 3–5. J Clin Med 11(24):7373. https://doi.org/10.3390/jcm11247373
doi: 10.3390/jcm11247373
pubmed: 36555989
pmcid: 9782058
Mohandas N, Gallagher PG (2008) Red cell membrane: past, present, and future. Blood 112(10):3939–3948. https://doi.org/10.1182/blood-2008-07-161166
doi: 10.1182/blood-2008-07-161166
pubmed: 18988878
pmcid: 2582001
Remigante A, Morabito R, Marino A (2021) Band 3 protein function and oxidative stress in erythrocytes. J Cell Physiol 236(9):6225–6234. https://doi.org/10.1002/jcp.30322
doi: 10.1002/jcp.30322
pubmed: 33559172
Li D, Zheng X, Zhang Y, Li X, Chen X, Yin Y, Hu J, Li J, Guo M, Wang X (2022) What should be responsible for eryptosis in chronic kidney disease? Kidney Blood Press Res 47(6):375–390. https://doi.org/10.1159/000522133
doi: 10.1159/000522133
pubmed: 35114677
Clementi A, Virzì GM, Milan Manani S, Battaglia GG, Ronco C, Zanella M (2022) Eryptosis in patients with chronic kidney disease: a possible relationship with oxidative stress and inflammatory markers. J Clin Med 11(23):7167. https://doi.org/10.3390/jcm11237167
doi: 10.3390/jcm11237167
pubmed: 36498741
pmcid: 9737176
Dias GF, Grobe N, Rogg S, Jörg DJ, Pecoits-Filho R, Moreno-Amaral AN, Kotanko P (2020) The role of eryptosis in the pathogenesis of renal anemia: insights from basic research and mathematical modeling. Front Cell Dev Biol 8:598148. https://doi.org/10.3389/fcell.2020.598148
doi: 10.3389/fcell.2020.598148
pubmed: 33363152
pmcid: 7755649
Lang F, Bissinger R, Abed M, Artunc F (2017) Eryptosis—the neglected cause of anemia in end stage renal disease. Kidney Blood Press Res 42(4):749–760. https://doi.org/10.1159/000484215
doi: 10.1159/000484215
pubmed: 29151105
Föller M, Lang F (2020) Ion transport in eryptosis, the suicidal death of erythrocytes. Front Cell Dev Biol 8:597. https://doi.org/10.3389/fcell.2020.00597
doi: 10.3389/fcell.2020.00597
pubmed: 32733893
pmcid: 7360839
Bissinger R, Qadri SM, Artunc F (2024) Eryptosis: a driver of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 33(2):220–225. https://doi.org/10.1097/mnh.0000000000000957
doi: 10.1097/mnh.0000000000000957
pubmed: 37987655
Bissinger R, Bhuyan AAM, Qadri SM, Lang F (2019) Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases. Febs j 286(5):826–854. https://doi.org/10.1111/febs.14606
doi: 10.1111/febs.14606
pubmed: 30028073
Virzì GM, Mattiotti M, Clementi A, Milan Manani S, Battaglia GG, Ronco C, Zanella M (2022) In vitro induction of eryptosis by uremic toxins and inflammation mediators in healthy red blood cells. J Clin Med 11(18):5329. https://doi.org/10.3390/jcm11185329
doi: 10.3390/jcm11185329
pubmed: 36142976
pmcid: 9501441
Alghareeb SA, Alfhili MA, Fatima S (2023) Molecular mechanisms and pathophysiological significance of eryptosis. Int J Mol Sci 24(6):5079. https://doi.org/10.3390/ijms24065079
doi: 10.3390/ijms24065079
pubmed: 36982153
pmcid: 10049269
Jiang Y, Li JH, Luo JF, Han QS, Zhu SL, Ma YJ, Zhang HD (2022) Hemodiafiltration improves red blood cell lifespan in patients with end-stage renal disease. Semin Dial 35(3):215–221. https://doi.org/10.1111/sdi.13037
doi: 10.1111/sdi.13037
pubmed: 34734675
Tozoni SS, Dias GF, Bohnen G, Grobe N, Pecoits-Filho R, Kotanko P, Moreno-Amaral AN (2019) Uremia and hypoxia independently induce eryptosis and erythrocyte redox imbalance. Cell Physiol Biochem 53:794–804. https://doi.org/10.33594/000000173
doi: 10.33594/000000173
pubmed: 31661199
Dias GF, Bonan NB, Steiner TM, Tozoni SS, Rodrigues S, Nakao LS, Kuntsevich V, Pecoits Filho R, Kotanko P, Moreno-Amaral AN (2018) Indoxyl sulfate, a uremic toxin, stimulates reactive oxygen species production and erythrocyte cell death supposedly by an organic anion transporter 2 (OAT2) and NADPH oxidase activity-dependent pathways. Toxins 10(7):280. https://doi.org/10.3390/toxins10070280
doi: 10.3390/toxins10070280
pubmed: 29976888
pmcid: 6071035
Bardyn M, Tissot JD, Prudent M (2018) Oxidative stress and antioxidant defenses during blood processing and storage of erythrocyte concentrates. Transfus Clin Biol 25(1):96–100. https://doi.org/10.1016/j.tracli.2017.08.001
doi: 10.1016/j.tracli.2017.08.001
pubmed: 28888839
Sudnitsyna J, Skverchinskaya E, Dobrylko I, Nikitina E, Gambaryan S, Mindukshev I (2020) Microvesicle formation induced by oxidative stress in human erythrocytes. Antioxidants 9(10):929. https://doi.org/10.3390/antiox9100929
doi: 10.3390/antiox9100929
pubmed: 32998418
pmcid: 7650597
Thavarajah S, Choi MJ (2019) The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach. Am J Kidney Dis 74(5):667–674. https://doi.org/10.1053/j.ajkd.2019.04.022
doi: 10.1053/j.ajkd.2019.04.022
pubmed: 31395400
Zhou QG, Jiang JP, Wu SJ, Tian JW, Chen JH, Yu XQ, Chen PY, Mei CL, Xiong F, Shi W, Zhou W, Liu XS, Sun SR, Xie D, Liu J, Xu X, Hou FF (2012) Current pattern of Chinese dialysis units: a cohort study in a representative sample of units. Chin Med J 125(19):3434–3439
pubmed: 23044302
Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458. https://doi.org/10.1056/NEJMoa1810742
doi: 10.1056/NEJMoa1810742
pubmed: 30365356
Sakaguchi Y, Hamano T, Wada A, Masakane I (2019) Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol 30(6):1037–1048. https://doi.org/10.1681/asn.2018101007
doi: 10.1681/asn.2018101007
pubmed: 31015255
pmcid: 6551773
Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D (2020) Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era. Kidney Med 2(5):589-599.e581. https://doi.org/10.1016/j.xkme.2020.06.008
doi: 10.1016/j.xkme.2020.06.008
pubmed: 33089137
pmcid: 7568064
Nakanishi T, Kuragano T (2024) Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clin Kidney J 17(3):sfae051. https://doi.org/10.1093/ckj/sfae051
doi: 10.1093/ckj/sfae051
pubmed: 38516524
pmcid: 10956400
Imai E, Imai A (2023) The comparison between vadadustat and daprodustat regarding dose, cost, and safety of treatment for renal anemia in non-dialysis patients with chronic kidney diseases. Intern Med. https://doi.org/10.2169/internalmedicine.2501-23
doi: 10.2169/internalmedicine.2501-23
pubmed: 37952952
pmcid: 10937144
Damarlapally N, Thimmappa V, Irfan H, Sikandari M, Madhu K, Desai A, Pavani P, Zakir S, Gupta M, Khosa MM, Kotak S, Varrassi G, Khatri M, Kumar S (2023) Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or without dialysis): a meta-analysis and systematic review. Cureus 15(10):e47430. https://doi.org/10.7759/cureus.47430
doi: 10.7759/cureus.47430
pubmed: 38021836
pmcid: 10659060
Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L, Garofalo C (2024) Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clin Kidney J 17(1):sfad143. https://doi.org/10.1093/ckj/sfad143
doi: 10.1093/ckj/sfad143
pubmed: 38186871
Begum S, Latunde-Dada GO (2019) Anemia of inflammation with an emphasis on chronic kidney disease. Nutrients 11(10):2424. https://doi.org/10.3390/nu11102424
doi: 10.3390/nu11102424
pubmed: 31614529
pmcid: 6835368
Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR (2019) Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 85(5):935–948. https://doi.org/10.1111/bcp.13877
doi: 10.1111/bcp.13877
pubmed: 30677788
pmcid: 6475730
Dreischer P, Duszenko M, Stein J, Wieder T (2022) Eryptosis: programmed death of nucleus-free, iron-filled blood cells. Cells 11(3):503. https://doi.org/10.3390/cells11030503
doi: 10.3390/cells11030503
pubmed: 35159312
pmcid: 8834305